Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 16 August 2022, 12:52 HKT/SGT
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting

Gaithersburg, MD, USA and Suzhou BioBay, China, Aug 16, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has developed a Peptide Docking Vehicle (PDoV(TM)) to achieve a peptide-enhanced GalNAc platform for siRNA drug delivery.

Sirnaomics' GalNAc platform takes advantage of a PDoV(TM) design that leverages selected small peptides which do not only possess an active endosomal escape property, but also provide two binding sites for the conjugation of dual-siRNA inhibitors. In cell culture and animal models, the PDoV-GalNAc platform has accelerated targeted gene knockdown more rapidly than with GalNAc alone, which is attributed to the rapid endosomal escape afforded by PDoV. In such studies, the maximal knockdown of the targeted gene occurred in the first week with the PDoV-GalNAc as compared to the third week with GalNAc alone.

The PDoV-GalNAc delivery technology can be effectively adapted for a dual-targeted siRNA therapeutic with different siRNAs, while targeting either two regions of the same mRNA or different mRNAs (of two drug targets). The dual-targeted PDoV-GalNAc siRNA construct has demonstrated an ability to increase the efficiency of targeted gene knockdown by 10 to 15 fold in vitro as compared to a single siRNA construct. Several novel siRNA drug candidates are currently under development using this technology, including STP135G, which targets the hepatocyte-expressed PCSK9 gene for Hypercholesterolemia, STP145G, which targets the viral mRNA for Hepatitis B virus, and STP165G, which targets hepatocyte-expressed Angiotensinogen for Hypertension.

"Sirnaomics has heavily invested in the GalNAc platform because it encompasses a unique design and innovative technology as compared to other platforms currently used for clinical development," said Dr. Patrick Lu, founder, Chairman of the Board, Executive Director, President and CEO of Sirnaomics. "Based on our PDoV-GalNAc and GalAhead(TM) -delivered siRNA drug candidates that are moving into clinical testing, Sirnaomics is well-positioned to develop new treatments for diseases related to liver hepatocytes. Our GalNAc and Polypeptide Nanoparticle (PNP) delivery technologies provide a solid foundation to serve broad unmet patient needs."

"Our in vitro and in vivo data has demonstrated the value of our PDoV design in addressing the challenge of improving endosomal escape for treatments developed with GalNAcdelivery," said Dr. David Evans, Executive Director and Chief Scientific Officer of Sirnaomics. "The PDoV-GalNAc delivery platform not only enhances the benefits of single siRNA therapeutics, but also advances the therapeutic efficacy of dual-targeted siRNA drug candidates. Sirnaomics' scientific team will continue to advance our novel RNAi therapeutics with development of such cutting-edge technology."

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at

David M. Evans, PhD
Executive Director and Chief Scientific Officer, Sirnaomics

Investor Relations:
Nigel Yip
Chief Financial Officer, China, Sirnaomics

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707

Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
MHI Group Delivers Two Large-Capacity Centrifugal Chillers for Singapore's Marina Bay District Cooling System  
Tuesday, October 4, 2022 10:58:00 AM
Rinnai and Toyota Start Exploring Hydrogen-Powered Cooking Methods  
Tuesday, October 4, 2022 10:02:00 AM
Bio Farma secures Multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)  
Oct 4, 2022 07:00 HKT/SGT
Gradiant, Global Water Solutions Provider, Expands Australia Presence and Capabilities  
Oct 4, 2022 06:55 HKT/SGT
Neste, Idemitsu Kosan, CHIMEI and Mitsubishi Corporation join forces to create a renewable plastics supply chain  
Monday, October 3, 2022 4:11:00 PM
Global Web 3.0 Gaming Platform ITSBLOC's $ITSB to Be Listed on MEXC  
Oct 3, 2022 15:00 HKT/SGT
Korindo in its Transition to an Eco-Friendly Company  
Oct 3, 2022 13:00 HKT/SGT
JCB Launches Kiwami Experience Exclusive Program  
Oct 3, 2022 11:00 HKT/SGT
Rovanpera crowned youngest ever champion with TOYOTA GAZOO Racing  
Monday, October 3, 2022 10:15:00 AM
EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong  
Oct 3, 2022 10:08 HKT/SGT
More Press release >>
More >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: